Youwen Zhou

Youwen Zhou is a Professor in the Department of Dermatology & Skin Science within the Faculty of Medicine at the University of British Columbia, based at Vancouver General Hospital. His clinical role as a Dermatologist complements his research focus on autoimmune and genetic skin disorders, particularly vitiligo, pigmentation diseases, and psoriasis.

His educational credentials include an MD, PhD, and Fellowships with the Royal College of Physicians and Surgeons of Canada (FRCPC) and the American Academy of Dermatology (FAAD). These qualifications underpin his expertise in both clinical practice and translational research.

Dr. Zhou's research centers on the genetics and genomics of skin diseases, with emphasis on vitiligo pathogenesis and innovative therapeutic development. His work bridges molecular mechanisms—such as aberrant immune responses in vitiligo and cutaneous T-cell lymphoma—with clinical applications, including JAK inhibitor therapies and biomarker discovery for personalized treatment approaches.

Analysis of his recent publications (2021-2025) reveals a dominant focus on vitiligo therapeutics (e.g., ruxolitinib, SPMs, tapinarof), international guideline development, and melanoma biomarker research. His work increasingly integrates computational methods for biomarker identification and emphasizes cross-population studies, as seen in Chinese cohort investigations.

No specific scientific awards were detailed in the source materials, though his leadership in the International Vitiligo Task Force underscores professional recognition.

As an active supervisor in UBC's Experimental Medicine graduate program, Dr. Zhou mentors students in thesis-based research and seeks interdisciplinary collaborations, including the UNCOVER-3 psoriasis trial. His public engagement includes media contributions explaining vitiligo mechanisms and hyperhidrosis.

His research operates within UBC's Department of Dermatology & Skin Science infrastructure, leveraging Vancouver General Hospital resources for translational studies from bench to bedside, with particular emphasis on immune-mediated skin disorders.